← All trials
NCT04939649
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2021
- Primary completion
- Oct 1, 2023
- Completion date
- Apr 1, 2024
- First posted
- Jun 25, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 104
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Trinity College DublinLead sponsor
- Trinity College DublinReponsible party - principal investigator
- University of DublinOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.